Artrya Limited (AU:AYA)
ASX:AYA
Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.10
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$4.10
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.58 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$651.98M
Enterprise ValueAU$422.88M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding159,799,500
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.19Price Target Upside50.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$10.00M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA very low debt load gives the company structural financial flexibility over the next 2–6 months: it reduces insolvency risk, lowers interest pressure on scarce cash, and makes raising incremental capital or committing to R&D and commercialization less constrained by fixed obligations.
Initial Commercial TractionRecording first revenues and strong percentage growth from a near-zero base indicates the product is entering commercial use. While dollar amounts are small, the trend is a durable signal that sales and go-to-market execution are beginning to work, a prerequisite for scaling margins and adoption.
Focused AI Cardiovascular ProductA focused product in AI-enabled cardiovascular imaging sits on a multi-year structural tailwind: hospitals seek diagnostic automation and workflow tools. A narrow, clinically relevant niche improves defensibility, allows targeted regulatory and clinical validation, and supports long-term commercial upside if adoption continues.
Bears Say
Sustained Cash BurnConsistently large negative operating and free cash flows are a persistent structural weakness: ongoing cash burn requires repeated external funding, risks dilution, and constrains product commercialization and regulatory studies unless the company materially improves conversion of R&D into sustainable revenue or secures durable financing.
No Demonstrated Operating LeverageThe firm has not shown scalable margins: fixed investment and SG&A are not yet offset by recurring revenue. Without demonstrable operating leverage, losses can persist as revenue scales, making profitability timing uncertain and reducing the margin of safety for longer-term investors and partners.
Equity Erosion And Negative ROEDeclining equity and sustained negative returns on equity reflect persistent value destruction from operations. This trend limits strategic optionality, raises the likelihood of dilutive capital raises, and signals that management must arrest losses to preserve shareholder value over the coming months.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.58 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$651.98M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 119 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 159,799,500 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.19 (50.85% Upside)
AU$6.19 (50.85% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.19
▲(50.85% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
Options Prices
Currently, No data available
---